Log in with your email address username.


[Comment] Gene therapy for the long term treatment of wet AMD

Age-related macular degeneration (AMD) is the most common cause of visual impairment in elderly populations of the developed world,1 and neovascular AMD (wet AMD) accounts for 90% of severe vision loss in patients with AMD. Wet AMD is associated with the upregulation of vascular endothelial growth factor (VEGF), which promotes angiogenesis and vascular permeability.2 Recently, therapies using recombinant anti-VEGF antibody fragments (eg, ranibizumab, bevacizumab, and aflibercept)3–5 to inhibit VEGF activity have shown that wet AMD can be treated successfully.